Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences (NASDAQ: MRVI) will announce its second quarter 2024 financial and operating results on August 7, 2024, after market close. The company will host a conference call and webcast on the same day at 2:00 p.m. PT/5:00 p.m. ET to discuss the results. Participants can join the call by dialing (888) 596-4144 or (646) 968-2525 using Conference ID 4292675. The webcast will also be available on the Maravai LifeSciences' investor relations website.
Maravai LifeSciences (NASDAQ: MRVI) has released its 2023 ESG report, highlighting progress in product innovation, employee empowerment, governance leadership, and sustainable growth. Key initiatives include the first stakeholder assessment to prioritize ESG issues, expanded GHG emissions reporting to include Scope 3, and the launch of the Analytical Sciences Center of Excellence. The report aligns with standards from the Global Reporting Initiative and Sustainability Accounting Standards Board, and United Nations Sustainable Development Goals. Highlights include over 3,000 products in their portfolio, 97% employee engagement in surveys, and $19K in employee donations matched by the company.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), is collaborating with Johns Hopkins University to establish a new RNA Innovation Center. This partnership aims to accelerate research in RNA therapeutics and discovery by providing funding, technology, and expertise to Hopkins researchers. TriLink's investment includes access to their proprietary RNA synthesis technology, CleanScript™, to advance mRNA development. The collaboration reinforces TriLink's commitment to nucleic acid-based therapies and will contribute to the development of advanced treatments for patients.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) announces its participation in investor conferences in May and June 2024. CEO Trey Martin and CFO Kevin Herde will engage in fireside chats at the RBC Healthcare Conference and Goldman Sachs Healthcare Conference, providing a live webcast for interested parties.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported Q1 2024 financial results with revenue of $64.2 million, a net loss of $(22.7) million, and adjusted EBITDA of $7.8 million. The company reaffirmed its full-year 2024 revenue guidance of $265.0 million to $285.0 million. Maravai highlighted partnerships with Lonza and Alphazyme, new product launches, and facility expansions. The company received industry recognition for innovation. Despite a 19% revenue decrease YoY, Maravai remains focused on growth and delivering value to customers.
TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive License and Supply Agreement with Lonza for its CleanCap mRNA capping technology. This agreement will allow Lonza to use TriLink's patented cap analogs for mRNA development and manufacturing services, enhancing the accessibility of CleanCap technology in the industry. CleanCap technology offers high capping efficiency and streamlines mRNA production processes, contributing to improved mRNA function and increased capped material yield.
Summary not available.
Summary not available.
Summary not available.
Summary not available.